Hirotsugu Yamada Selected Research

Scarlet Red (Sudan IV)

11/2023	Olive mill wastewater and hydroxytyrosol inhibits atherogenesis in apolipoprotein E-deficient mice.
6/2021	Inhibition of S1P Receptor 2 Attenuates Endothelial Dysfunction and Inhibits Atherogenesis in Apolipoprotein E-Deficient Mice.
11/2019	Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hirotsugu Yamada Research Topics

Disease

19	Atherosclerosis 11/2023 - 02/2011
13	Heart Failure 01/2024 - 11/2004
13	Inflammation (Inflammations) 01/2023 - 02/2010
12	Hypertension (High Blood Pressure) 12/2019 - 10/2004
11	Type 2 Diabetes Mellitus (MODY) 02/2024 - 08/2015
9	Cardiovascular Diseases (Cardiovascular Disease) 11/2023 - 06/2013
8	Neoplasms (Cancer) 12/2023 - 01/2017
8	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 12/2014
7	Atherosclerotic Plaque (Atheroma) 11/2019 - 09/2011
6	Atrial Fibrillation 03/2023 - 06/2003
5	Thrombosis (Thrombus) 03/2023 - 12/2011
4	Body Weight (Weight, Body) 11/2023 - 02/2010
4	Insulin Resistance 09/2022 - 02/2010
4	Dyslipidemias (Dyslipidemia) 01/2021 - 12/2014
4	Carotid Artery Diseases 01/2020 - 09/2010
4	Myocardial Infarction 01/2019 - 03/2002
3	Breast Neoplasms (Breast Cancer) 12/2023 - 01/2020
3	Infections 01/2023 - 02/2011
3	Left Ventricular Dysfunction 01/2023 - 02/2011
3	Cardiomyopathies (Cardiomyopathy) 01/2022 - 01/2018
3	Hyperuricemia 01/2022 - 06/2016
3	Diabetes Mellitus 01/2021 - 12/2014
3	Fibrosis (Cirrhosis) 01/2021 - 07/2015
3	Acute Coronary Syndrome 03/2019 - 10/2015
3	Ischemia 01/2018 - 01/2013
3	Essential Hypertension 01/2015 - 10/2004
3	Myocardial Ischemia (Ischemic Heart Diseases) 11/2013 - 11/2007
3	Myocarditis (Carditis) 01/2013 - 02/2011
2	Bites and Stings (Sting) 11/2023 - 11/2021
2	Venous Thromboembolism 07/2022 - 01/2018
2	Cardiac Arrhythmias (Arrythmia) 01/2021 - 01/2017
2	Spasm (Spasms) 01/2018 - 10/2017
2	Arteriosclerosis 01/2016 - 01/2015
2	Hypotension (Low Blood Pressure) 08/2015 - 12/2006
2	Sarcoidosis (Schaumann Disease) 06/2015 - 01/2011
2	Edema (Dropsy) 01/2014 - 01/2013

Drug/Important Bio-Agent (IBA)

12	LipidsIBA 11/2023 - 07/2015
9	Biomarkers (Surrogate Marker)IBA 01/2021 - 02/2011
8	ApolipoproteinsIBA 11/2023 - 11/2016
8	Apolipoproteins E (ApoE)IBA 11/2021 - 10/2015
7	Eicosapentaenoic AcidIBA 03/2019 - 12/2014
7	Docosahexaenoic AcidsIBA 03/2019 - 12/2014
5	AnticoagulantsIBA 07/2022 - 06/2013
4	Brain Natriuretic Peptide (Natrecor)FDA Link 09/2023 - 12/2014
4	C-Reactive ProteinIBA 01/2023 - 09/2011
4	Angiotensin IIIBA 01/2021 - 12/2006
4	Factor Xa (Coagulation Factor Xa)IBA 01/2021 - 10/2015
4	Hypoglycemic Agents (Hypoglycemics)IBA 01/2020 - 01/2016
3	Sodium-Glucose Transporter 2 InhibitorsIBA 02/2024 - 01/2016
3	DNA (Deoxyribonucleic Acid)IBA 11/2023 - 01/2019
3	InterferonsIBA 11/2023 - 05/2015
3	Scarlet Red (Sudan IV)IBA 11/2023 - 11/2019
3	RivaroxabanIBA 07/2022 - 10/2015
3	Febuxostat FDA Link 01/2022 - 06/2016
3	HDL CholesterolIBA 12/2021 - 01/2015
3	CanagliflozinIBA 01/2021 - 01/2017
3	RNA (Ribonucleic Acid)IBA 05/2020 - 02/2011
3	Uric Acid (Urate)IBA 01/2020 - 01/2015
3	Dipeptidyl-Peptidase IV InhibitorsIBA 11/2019 - 08/2015
3	SodiumIBA 01/2018 - 07/2016
3	Sitagliptin Phosphate (Januvia)FDA Link 11/2017 - 01/2016
3	Dobutamine FDA LinkGeneric 10/2017 - 03/2002
3	CreatinineIBA 01/2017 - 06/2011
3	DiureticsIBA 07/2016 - 01/2011
3	Arachidonic Acid (Vitamin F)IBA 12/2015 - 12/2014
3	Proteins (Proteins, Gene)FDA Link 05/2015 - 01/2013
3	LDL CholesterolIBA 01/2015 - 02/2010
2	ipragliflozinIBA 02/2024 - 01/2016
2	Mitochondrial DNA (mtDNA)IBA 11/2023 - 11/2021
2	Acetylcholine (Acetylcholine Chloride)FDA Link 11/2023 - 10/2017
2	cyclic guanosine monophosphate-adenosine monophosphateIBA 11/2023 - 11/2021
2	Blood Glucose (Blood Sugar)IBA 11/2023 - 01/2017
2	edoxabanIBA 07/2022 - 01/2018
2	Amyloid (Amyloid Fibrils)IBA 01/2022 - 12/2019
2	Triglycerides (Triacylglycerol)IBA 12/2021 - 06/2011
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2019 - 01/2016
2	Toll-Like Receptor 9IBA 01/2019 - 01/2018
2	Peptide Hydrolases (Proteases)FDA Link 10/2018 - 02/2011
2	CollagenIBA 10/2018 - 10/2015
2	SymportersIBA 01/2018 - 01/2017
2	Thrombin FDA Link 01/2018 - 02/2011
2	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 01/2017
2	Indicators and Reagents (Reagents)IBA 01/2017 - 09/2011
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 11/2016 - 12/2014
2	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 11/2016 - 12/2014
2	Therapeutic UsesIBA 01/2016 - 09/2011
2	CytokinesIBA 01/2016 - 02/2011
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 10/2015 - 08/2015
2	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2015 - 01/2011
2	AlbuminsIBA 01/2015 - 02/2010
2	GhrelinIBA 12/2014 - 11/2013
2	oxidized low density lipoproteinIBA 01/2014 - 02/2010

Therapy/Procedure

17	Therapeutics 12/2023 - 12/2003
4	Stents 03/2019 - 07/2011
4	Cardiac Rehabilitation 10/2018 - 01/2014
3	Drug Therapy (Chemotherapy) 01/2023 - 06/2013
2	Catheter Ablation 01/2022 - 01/2011
2	Percutaneous Coronary Intervention 11/2021 - 01/2015
2	Exercise Therapy (Therapy, Exercise) 01/2020 - 01/2016
2	Aftercare (After-Treatment) 01/2017 - 10/2004